| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
900,000 |
| Market
Cap: |
376.20(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4001 - $0.590001 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Evoke Pharma is a pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Co. is developing its primary product, Gimoti™ (metoclopramide) nasal spray, a nasally-administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Diabetic gastroparesis is a GI disorder, in which food in an individual's stomach takes too long to empty resulting in a variety of GI symptoms and systemic metabolic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
41 |
41 |
41 |
| Total Sell Value |
$0 |
$180 |
$180 |
$180 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
1 |
1 |
1 |
| End Date |
2025-04-06 |
2025-01-03 |
2024-07-05 |
2023-07-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Donofrio Matthew J |
Chief Executive Officer |
• • – |
2025-03-21 |
4 |
A |
$2.80 |
$2,797 |
D/D |
1,000 |
9,820 |
|
- |
|
| Kowieski Mark |
Chief Financial Officer |
• – – |
2025-03-20 |
4 |
A |
$3.21 |
$14,463 |
D/D |
4,500 |
4,916 |
|
- |
|
| Donofrio Matthew J |
Chief Executive Officer |
• • – |
2025-02-28 |
4 |
A |
$3.65 |
$24,999 |
D/D |
6,849 |
8,820 |
|
- |
|
| Mack Daniel |
10% Owner |
– – • |
2025-01-28 |
4 |
S |
$4.39 |
$180 |
I/I |
(41) |
148,153 |
|
- |
|
| Mack Daniel |
10% Owner |
– – • |
2024-11-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
148,194 |
|
- |
|
| Kowieski Mark |
Chief Financial Officer |
• – – |
2024-05-22 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,000 |
|
-100% |
|
| Gonyer David A |
President and CEO |
• • – |
2020-12-14 |
4 |
S |
$2.94 |
$70,425 |
D/D |
(23,954) |
339,782 |
|
- |
|
| Gonyer David A |
President and CEO |
• • – |
2020-12-11 |
4 |
S |
$2.90 |
$139,333 |
D/D |
(48,046) |
363,736 |
|
- |
|
| Donofrio Matthew J |
Exec VP, Chief Bus. Officer |
• – – |
2020-12-11 |
4 |
S |
$2.91 |
$117,439 |
D/D |
(40,357) |
283,997 |
|
- |
|
| Donofrio Matthew J |
Exec VP, Chief Bus. Officer |
• – – |
2020-12-10 |
4 |
S |
$2.95 |
$16,647 |
D/D |
(5,643) |
324,354 |
|
- |
|
| Donofrio Matthew J |
Exec VP, Chief Bus. Officer |
• – – |
2020-12-09 |
4 |
OE |
$0.40 |
$18,400 |
D/D |
46,000 |
329,997 |
|
- |
|
| Gonyer David A |
President and CEO |
• • – |
2020-12-09 |
4 |
OE |
$0.40 |
$28,800 |
D/D |
72,000 |
411,782 |
|
- |
|
| Carlson Marilyn R. |
Chief Medical Officer |
• – – |
2020-09-01 |
4 |
A |
$1.05 |
$21,250 |
D/D |
20,238 |
51,876 |
|
- |
|
| Gonyer David A |
President and CEO |
• • – |
2020-09-01 |
4 |
A |
$1.05 |
$21,250 |
D/D |
20,238 |
339,782 |
|
- |
|
| Donofrio Matthew J |
Exec VP, Chief Bus. Officer |
• – – |
2020-09-01 |
4 |
A |
$1.05 |
$21,250 |
D/D |
20,238 |
283,997 |
|
- |
|
| Donofrio Matthew J |
Exec VP, Chief Bus. Officer |
• – – |
2020-03-02 |
4 |
A |
$0.85 |
$21,250 |
D/D |
25,000 |
263,759 |
|
- |
|
| Donofrio Matthew J |
Exec VP, Chief Bus. Officer |
• – – |
2018-08-31 |
4 |
A |
$1.63 |
$21,249 |
D/D |
13,036 |
238,759 |
|
- |
|
| Carlson Marilyn R. |
Chief Medical Officer |
• – – |
2018-08-31 |
4 |
A |
$1.63 |
$5,055 |
D/D |
3,101 |
31,638 |
|
- |
|
| Gonyer David A |
President and CEO |
• • – |
2018-08-31 |
4 |
A |
$1.63 |
$11,249 |
D/D |
6,901 |
319,544 |
|
- |
|
| Lvpmc, Llc |
10% Owner |
– – • |
2018-08-20 |
4 |
B |
$2.35 |
$1,175,000 |
I/I |
500,000 |
48,449 |
1.5 |
- |
|
| Gonyer David A |
President and CEO |
• • – |
2017-08-31 |
4 |
A |
$2.15 |
$17,716 |
D/D |
8,240 |
312,643 |
|
- |
|
| Donofrio Matthew J |
Exec VP, Chief Bus. Officer |
• – – |
2017-08-31 |
4 |
A |
$2.15 |
$2,397 |
D/D |
1,115 |
225,723 |
|
- |
|
| Gonyer David A |
President and CEO |
• • – |
2017-02-28 |
4 |
A |
$1.60 |
$19,200 |
D/D |
12,000 |
304,403 |
|
- |
|
| Donofrio Matthew J |
Exec VP, Chief Bus. Officer |
• – – |
2017-02-28 |
4 |
A |
$1.60 |
$19,200 |
D/D |
12,000 |
224,608 |
|
- |
|
| Carlson Marilyn R. |
Chief Medical Officer |
• – – |
2017-02-28 |
4 |
A |
$1.60 |
$12,600 |
D/D |
7,875 |
24,514 |
|
- |
|
52 Records found
|
|
Page 1 of 3 |
|
|
